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Abstract 
Background 
Nonalcoholic fatty liver disease (NAFLD) in one of the most common liver diseases characterized by 
increases in serum aminotransferases and accumulation of fat in the liver. NAFLD can lead to diabetes, 
cardiovascular complications, end stage liver disease, liver cirrhosis, and hepatocellular carcinoma. At the 
moment there is no drug treatment for the management of NAFLD. Other treatment options should be 
explored for this disease that can progress to liver cirrhosis and hepatocellular carcinoma. Individual 
studies and systematic analysis have shown that the consumption of probiotics can decrease liver 
aminotransferase levels in adults with NAFLD. 
Methods 
An extensive literature search was performed using MEDLNE-Ovid, Web of Science, and CINAHL using the 
terms “probiotics,” and “ nonalcoholic fatty liver disease.” The studies were then limited to randomized 
control trials and restricted to human studies in the English language and performed within the last 5 
years. Inclusion criteria included studies on adults diagnosed with NAFLD via ultrasonography or liver 
tissue biopsy. Studies were assessed for quality using GRADE criteria. 
Results 
Two studies were found which met the inclusion and exclusion criteria. Both studies were randomized 
control studies performed in Spain, Aller et al, and the second study performed in Iran, Nabavi et al. Both 
studies showed that taking probiotics reduced liver aminotransferases levels in patients with NAFLD. The 
Aller et al study found that the intervention group was statistically different at baseline and at 3 months 
post probiotic therapy for ALT and AST. The Nabavi et al study found that at the end of the 2 weeks 
probiotic yogurt consumption results in a reduction of 4.67 and 5.42 in ALT and AST levels, respectively, 
compared to the conventional yogurt group. 
Conclusion 
The studies demonstrated a reduction in liver aminotransferases with treatment of probiotics in patients 
with nonalcoholic fatty liver disease. 
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Abstract   
 
Background 
Nonalcoholic fatty liver disease (NAFLD) in one of the most common liver diseases 
characterized by increases in serum aminotransferases and accumulation of fat in the 
liver. NAFLD can lead to diabetes, cardiovascular complications, end stage liver disease, 
liver cirrhosis, and hepatocellular carcinoma. At the moment there is no drug treatment 
for the management of NAFLD. Other treatment options should be explored for this 
disease that can progress to liver cirrhosis and hepatocellular carcinoma. Individual 
studies and systematic analysis have shown that the consumption of probiotics can 
decrease liver aminotransferase levels in adults with NAFLD.  
 
Methods 
An extensive literature search was performed using MEDLNE-Ovid, Web of Science, 
and CINAHL using the terms “probiotics,” and “ nonalcoholic fatty liver disease.” The 
studies were then limited to randomized control trials and restricted to human studies in 
the English language and performed within the last 5 years. Inclusion criteria included 
studies on adults diagnosed with NAFLD via ultrasonography or liver tissue biopsy.  
Studies were assessed for quality using GRADE criteria.  
 
Results 
Two studies were found which met the inclusion and exclusion criteria. Both studies were 
randomized control studies performed in Spain, Aller et al, and the second study 
performed in Iran, Nabavi et al. Both studies showed that taking probiotics reduced liver 
aminotransferases levels in patients with NAFLD. The Aller et al study found that the 
intervention group was statistically different at baseline and at 3 months post probiotic 
therapy for ALT and AST. The Nabavi et al study found that at the end of the 2 weeks 
probiotic yogurt consumption results in a reduction of 4.67 and 5.42 in ALT and AST 
levels, respectively, compared to the conventional yogurt group. 
 
Conclusion   
The studies demonstrated a reduction in liver aminotransferases with treatment of 
probiotics in patients with nonalcoholic fatty liver disease.  
 
Keywords Probiotics, nonalcoholic fatty liver disease, liver aminotransferases  
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Use of Probiotics in patients with Nonalcoholic Fatty Liver 
Disease and Reduction of Liver Aminotransferases 
BACKGROUND 
 The prevalence of nonalcoholic fatty liver disease (NAFLD) is rising and 
becoming the most common form of chronic liver disease in adults and children.1 
NAFLD is a broader term used to describe hepatic changes seen in patients with steatosis, 
nonalcoholic steatohepatitis, more progressive liver diseases like cirrhosis and end stage 
liver disease, all of which can lead to the development of hepatocellular carcinoma.1 The 
pathology behind NAFLD is an active area of research. There are several predicted 
factors that contribute to NAFLD such as lifestyle, diet, exercise, genetic predisposition, 
and hormonal dysregulation.2 Research has shown that intestinal microflora contributes to 
NAFLD by way of translocation of endotoxins and ethanol produced by the intestinal 
lumen to the mesenteric circulation. The endotoxins then activate Kupffer cells located in 
the liver and thus stimulate the production of TNF alpha and IL-6.1 One study3 states that 
the prevalence is an estimated 2.8% to 46% throughout the world and varies depending 
on the study population and the diagnostic tool that is used to diagnose NAFLD (ie: 
blood serum liver enzymes, ultrasound, or liver biopsy).3 The development of NAFLD 
has been linked to an increase risk of diabetes, cardiovascular problems, cirrhosis and 
even hepatocellular carcinoma. One study4 states that individuals with NALFD have a 
higher mortality rate than healthy people.4  
 Although the prevalence of NAFLD is becoming more and more common, there 
is no approved treatment for this disease. There have been many studies5 that look into 
the role of nutrients in the development, progression, and treatment of NAFLD. In adults 
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and children, obesity is the main cause; therefore, data reviewed confirms that weight 
loss and life style changes remain the first choice treatment for adults and children with 
NAFLD.5 Other treatment modalities include insulin sensitizers, antioxidants, and 
hepatoprotective agents such as ursodeoxycholic acid, and the use of probiotics.4,1 The 
use of probiotics in the setting of NAFLD is a new area of research that warrants more 
studies to confirm its potential benefit.   
 Probiotics are live microorganisms which when consumed confer a healthy 
benefit to the host.6 Probiotics have numerous reported effects such as maintaining 
intestinal microflora, reducing cholesterol levels, promoting a healthy immune system, 
lowering risk of cancers, and helping with diabetes. It is shown that changes in our 
intestinal microbiome composition could increase endotoxemia in response to a high-fat 
diet, which in turn would trigger the development of obesity and diabetes.7 In summary, 
given that obesity is a common risk factor in people with NAFLD, the use of probiotics 
could potentially be a treatment with promising benefits either as an alternative therapy 
or as an adjunct therapy in combination with other therapeutic modalities. Probiotics 
come in many forms including pills, gummy form, mix drinks, and can be find in 
multiple yogurts. They can be found at any store and are cost friendly. There are no 
studies that show risks associated with taking probiotics. Taking into consideration the 
facts above, one would find it a reasonable alternative or adjunct therapy in reducing the 
effects of NAFLD.  
 NAFLD is characterized by elevated serum aminotransferases levels and fat 
accumulation in the liver. Alanine aminotransferase (ALT) and aspartate 
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aminotransferase (AST) are liver markers measured with a blood test and can be useful in 
telling us about overall liver function and are indicators of hepatocellular injury.8 
Although there are other ways of measuring liver disease, the 2 mentioned above are the 
focus of this review. The aim of this review is to focus on the role of probiotics in 
reducing liver aminotransferases in patients with NAFLD.  
METHODS 
An exhaustive literature search was performed using MEDLINE-Ovid, Web of 
Science, and CINAHL using the terms “probiotics,” and “ nonalcoholic fatty liver 
disease.” With Web of Science, the search also included the search term “liver 
aminotransferases.” The search was limited to randomized control trials (RCT) and 
restricted to human studies in the English language. The search was also restricted to 
studies published within the last 5 years. In addition to using the above search databases, 
articles pulled from certain references were used for relevant information. The studies 
were then appraised and assessed for quality using GRADE.9 
RESULTS  
 The initial search using MEDLINE-Ovid yielded 5 articles. Using PICO for 
inclusion and exclusion criteria, the 5 articles were narrowed down to 2 randomized 
control studies8,10 (see Table 1). Web of science yielded these same 2 articles. A search 
with the key terms on CINAHL yielded 8 results, all of which did not meet eligibility 
criteria or did not consist of randomized control studies.  
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Aller et al  
Study Description—This randomized control study,10 published in 2011 in the 
European Review for Medical and Pharmacological Sciences, examined a cohort of 30 
patients diagnosed with NALFD. The main purpose of this study was to examine the 
effects of taking probiotic tablets daily on liver aminotransferases and gammaglutamine 
transferase levels. The diagnosis of NAFLD was made via percutaneous liver biopsy. The 
exclusion criteria included patients with hepatitis B or C, cytomegalovirus, Epstein Barr 
infections, non organ-specific autoantibodies, alcohol consumption, diabetes mellitus, 
impaired glucose tolerance, medications (ie, statins and blood pressure), and hereditary 
defects (iron and copper diseases).10 The study was a double blind randomized clinical 
trial that included 2 groups. Group I (intervention group) was given 1 tablet a day of 500 
million of Lactobacillus bulgaricus and Streptococcus thermophile. Group II was the 
control group that was given a placebo tablet of 120 mg of starch. Each participant was 
given 90 tablets making it a 3-month treatment window. Food intake was recorded at 
baseline and after the 3 months. The participants recorded their food intake for 3 days and 
incorporated the use of food scales to enhance portion size accuracy.10 
Alanine amino transferases, aspartate aminotransferase, bilirubin, and 
gammaglutamine transferase were determined by enzymatic colorimetric assay.9 Other 
parameters were measured: weight, blood pressure, glucose, total cholesterol, 
triglycerides, and Il6 and TNF alpha. These were measured at baseline and after the 3-
month period.  
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Study Results—Out of the 30 patients that started the study, 28 participants 
finished out the study. They excluded the 2 participants because they consumed less than 
90% of the tablets they were given. The results after 3 months showed that group I had an 
improvement (a reduction) of ALT, AST, and gammaglutamine transferase levels after 3-
months of probiotic therapy compared to baseline. This is in comparison to the control 
group that had increased levels of ALT, AST, and gammaglutamine transferase (See 
Table II). The results were analyzed with a confidence interval of 95% and a significant 
p-value of <0.05. When comparing intergroup statistics, it showed that the intervention 
group was statistically different at baseline and at 3-months post probiotic therapy for 
ALT and AST. When comparing the placebo group vs. the intervention group there is a 
difference of 11 points when comparing differences in ALT. Overall, the study concluded 
that a tablet containing 500 million of Lactobacillus bulgarius and Streptococcus 
thermophiles in patients with NAFLD was associated with ALT and AST improvement.1 
The limitations to this study include a small cohort, short treatment window, and the use 
of surrogate outcomes. The large standard deviations suggest that future studies should 
include a larger cohort of participants or following the participants for a longer duration 
of time. The study used surrogate outcomes (ALT and AST) to indirectly measure liver 
disease. Using these biomarkers to measure liver disease is not a direct way to measure 
whether or not liver function is improving.  
Nabavi et al  
Study Description—This randomized control study,8 published in 2014 in the 
American Dairy Science Association, examined a cohort of 72 patients with NAFLD, 
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aged 23-63 years, with body mass index ranging from 25-40 kg/m2.8 Recruitment of the 
participants were patients referred over from a gastroenterologist who had just diagnosed 
these participants as new cases of NAFLD. The diagnosis was made via ultrasonography 
rather than liver biopsy. The exclusion criteria included patients with kidney disease, 
another type of liver disease, hepatitis B or C, inflammatory intestinal disease, thyroid 
disorders, immunodeficiency disease, Wilson disease, hemochromatosis, lactose 
intolerance, tobacco or alcohol use, pregnant or breast feeding, receiving cholesterol-
lowering medication, estrogen, progesterone, or diuretics, and consumption of probiotic 
yogurt or other probiotic products within the last 2 months. The study was a double blind 
randomized clinical trial that included 2 groups. There were no differences in gender and 
age distribution between the 2 groups. Group I had a mean age of 49.4 and group II had a 
mean age of 44.3.8 One group was given probiotic enriched yogurt and the other group 
was given conventional yogurt. ALTs and ASTs were measured using Bio System kits 
and an auto analyzer set. Fasting blood glucose, triglycerides, HDL, and LDL were also 
measured. The length of the study was 2 weeks with no participants dropping out.8   
Study Results—All the participants of the study ended without compliance 
issues. The study found that at the end of the 2 weeks, probiotic yogurt consumption 
resulted in a reduction of 4.67 and 5.42 in ALT and AST levels, respectively, compared 
to the conventional yogurt group.8 The probiotic group had a decrease in the number of 
abnormal cases of ALT after intervention (13 to 10) whereas the conventional group had 
no change.8 The results of this study trends towards a positive result similar to that of the 
Aller et al10 study.  
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DISCUSSION 
 The prevalence of NAFLD is significant and with the prevalence increasing 
worldwide, pharmacological and non-pharmacological treatments are being sought out. 
The use of probiotics in liver disease, specifically NAFLD, has little data that supports it. 
Results emerging from the above studies,8,10 demonstrate that an acute course of daily 
probiotics induced a reduction in liver aminotransferases in adults diagnosed with 
NAFLD. Data from the Aller et al10 study are in keeping with the results of the Nabavi et 
al8 study. Within the studies,8,10 there was no adverse reactions when taking the 
probiotics.  
 The Aller et al10 study was a pilot trail designed to evaluate the effects of acute 
treatment with a mixture containing 500 million of Lactobacillus bulgaricus and 
Streptococcus thermophilus per day in patients with NAFLD. The study concludes that in 
conditions in which intestinal microflora may be a cofactor of NAFLD, modification of 
gut flora with the use of probiotics may be a potential treatment.  
Another double blind RCT11 done on children showed that obese children with 
NAFLD (average age of 10.7) treated with Lactobacillus rhamnosus for 8 weeks showed 
a significant reduction in ALT amongst other parameters. The research and studies done 
around the use of probiotics and its ability to reduce liver aminotransferases warrants its 
consideration as a therapeutic modality in slowing down the progression and 
development of NAFLD as well as treating the disease.  
There is a lack of randomized control studies regarding this topic. With more 
studies that contain a larger sample size along with a longer duration of treatment, a 
better understanding of the effects of using probiotics for NAFLD will be uncovered. 
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Both studies8,10 used blood serum ALT and AST levels to measure the effectiveness of 
probiotics. Given that these parameters indirectly measure liver disease, it is hard to 
examine if it is actually helping the progression and treatment of the disease. In future 
studies, measuring fatty deposits as a direct biomarker for NAFLD would give a better 
idea on its benefits in the progression of NAFLD. Within the studies, had the panel 
followed the participants for a longer duration of time to see if they needed a liver 
transplant, this would be a more direct way to measure the effectiveness of probiotics.  
CONCLUSION 
 There is evidence presented in the Aller et al10 and Nabavi et al8 studies that 
consuming probiotics in any form correlates with improvement of liver aminotransferases 
in patients with NAFLD. Both studies did not mention any harm or adverse reactions in 
using probiotics. Despite the lack of RCTs that contain a larger sample size, the studies 
reviewed within this article as well as research done on this topic show enough of a 
positive trend that medical providers should suggest this as a treatment option if patients 
wish to try it. If patients want to try probiotics, providers should let them know that 
taking probiotics have not been shown to have any adverse reactions and may or may not 
help with improving liver aminotransferase levels. However, with any new treatment 
modality, the more studies that are done, the better the validation of the effectiveness of 
the treatment. Indeed, the effects on liver enzymes and on some other parameters related 
to NAFLD such as BMI, glucose levels, and lipid levels, the low cost, and no adverse 
effects, it would appear that probiotics as an alternative option or adjunct therapy would 
be a well-reasoned recommendation.  
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Table 1: Quality Assessment of Reviewed Articles 
Study 
Desig
n 
Downgrade Criteria Upgrad
e 
Criteria 
Qualit
y 
Limitatio
ns 
Indirectne
ss 
Inconsisten
cy 
Imprecisi
on 
Publicati
on bias 
Aller 
et al9 
RCT Not 
Serious 
Serious a Not Serious Serious b Unlikely N/a Low 
Naba
vi et 
al8 
RCT Not 
Serious 
Seriousa  Not Serious Seriousb Unlikely N/a Low 
 
a Use of surrogate outcomes (AST, ALT, and GGT)  
b Small sample size  
 
 
 
Table II: Changes in ALT and AST from Aller et al Study9 
                                                                              
                                                      Placebo                                           
 Baseline 3 Months  Baseline  3 months 
ALT 60.7±32.1  64.8±35.5 67.7±25.1  60.4±30.4 
AST 31.7±13.1 36.4±13.8 41.3±15.5  35.6±10.4 
Gammaglutamine transferase  82.1±55.1 83.6±65.3 118.2±63.1 107.7±60.8 
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